Liraglutide Reference

Educational, not medical advice reference for Liraglutide: GLP-1, Fat Loss; regulatory status, evidence posture, source review, and schedule not…

Plain English

What it is
Liraglutide is an FDA-approved prescription medicine, not an experimental or research-only compound. It is a GLP-1 receptor agonist, meaning it copies a natural gut hormone that helps lower blood sugar and curb appetite. It is sold under the brand names Saxenda (for weight management) and Victoza (for type 2 diabetes).
What people use it for
Saxenda is approved to help adults and some adolescents reduce excess body weight and keep it off, paired with a lower-calorie diet and more physical activity. Victoza is the version used to help control blood sugar in people with type 2 diabetes.
What the science shows
This is one of the more established, approved GLP-1 medicines, so it carries strong human evidence behind its approved uses. The most common side effects are gut-related, including nausea, diarrhea, constipation, and vomiting, which is the usual pattern for this class of drug.
The catch
Liraglutide carries the FDA's most serious safety alert, a boxed warning: it caused thyroid C-cell tumors in rats and mice, and it must not be used by people with a personal or family history of medullary thyroid cancer (MTC) or the genetic syndrome MEN 2. It is prescription-only and belongs under a prescriber's care, and getting amounts wrong is a real risk, so it is not a casual supplement.

Reference summary

Daily liraglutide tracking is label-reference content and should be separated from weekly GLP-1 reminder logic.

Regulatory and posture

Categories
GLP-1, Fat Loss
Aliases
Saxenda label reference, Victoza active ingredient
Evidence posture
human
Regulatory status
FDA-approved liraglutide label references exist for branded products; this entry uses Saxenda obesity-management label context.
Content review status
label verified

Selected public sources

Related tools

For research and educational purposes only. Not medical advice.